Avidity Biosciences RNA Stock
Avidity Biosciences Price Chart
Avidity Biosciences RNA Financial and Trading Overview
| Avidity Biosciences stock price | 72.18 USD |
| Previous Close | 34.04 USD |
| Open | 34.37 USD |
| Bid | 33.69 USD x 1200 |
| Ask | 33.83 USD x 600 |
| Day's Range | 33.47 - 35.14 USD |
| 52 Week Range | 21.51 - 56 USD |
| Volume | 2.73M USD |
| Avg. Volume | 1.6M USD |
| Market Cap | 4.07B USD |
| Beta (5Y Monthly) | 0.947 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 67.24 USD |
RNA Valuation Measures
| Enterprise Value | 2.05B USD |
| Trailing P/E | N/A |
| Forward P/E | -11.141913 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 455.78076 |
| Price/Book (mrq) | 3.0618536 |
| Enterprise Value/Revenue | 229.572 |
| Enterprise Value/EBITDA | -4.762 |
Trading Information
Avidity Biosciences Stock Price History
| Beta (5Y Monthly) | 0.947 |
| 52-Week Change | -27.084% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 56 USD |
| 52 Week Low | 21.51 USD |
| 50-Day Moving Average | 30.85 USD |
| 200-Day Moving Average | 34.22 USD |
RNA Share Statistics
| Avg. Volume (3 month) | 1.6M USD |
| Avg. Daily Volume (10-Days) | 2.94M USD |
| Shares Outstanding | 120.52M |
| Float | 91.75M |
| Short Ratio | 11.56 |
| % Held by Insiders | 5.16% |
| % Held by Institutions | 112.41% |
| Shares Short | 16.34M |
| Short % of Float | 13.68% |
| Short % of Shares Outstanding | 13.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -8360.90% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.46% |
| Return on Equity (ttm) | -34.19% |
Income Statement
| Revenue (ttm) | 8.93M USD |
| Revenue Per Share (ttm) | 0.07 USD |
| Quarterly Revenue Growth (yoy) | -55.60% |
| Gross Profit (ttm) | -327324000 USD |
| EBITDA | -430345984 USD |
| Net Income Avi to Common (ttm) | -369220000 USD |
| Diluted EPS (ttm) | -3 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.38B USD |
| Total Cash Per Share (mrq) | 11.45 USD |
| Total Debt (mrq) | 5.97M USD |
| Total Debt/Equity (mrq) | 0.45 USD |
| Current Ratio (mrq) | 16.909 |
| Book Value Per Share (mrq) | 11.026 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -355319008 USD |
| Levered Free Cash Flow (ttm) | -245727248 USD |
Profile of Avidity Biosciences
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 10578 Science Center Drive |
| ZIP | 92121 |
| Phone | 858 401 7900 |
| Website | https://www.aviditybiosciences.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 391 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Q&A For Avidity Biosciences Stock
What is a current RNA stock price?
Avidity Biosciences RNA stock price today per share is 72.18 USD.
How to purchase Avidity Biosciences stock?
You can buy RNA shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Avidity Biosciences?
The stock symbol or ticker of Avidity Biosciences is RNA.
Which industry does the Avidity Biosciences company belong to?
The Avidity Biosciences industry is Biotechnology.
How many shares does Avidity Biosciences have in circulation?
The max supply of Avidity Biosciences shares is 150.68M.
What is Avidity Biosciences Price to Earnings Ratio (PE Ratio)?
Avidity Biosciences PE Ratio is now.
What was Avidity Biosciences earnings per share over the trailing 12 months (TTM)?
Avidity Biosciences EPS is -4.19 USD over the trailing 12 months.
Which sector does the Avidity Biosciences company belong to?
The Avidity Biosciences sector is Healthcare.
Avidity Biosciences RNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23613.31 USD — |
+0.22
|
3.54B USD — | 23527.97 USD — | 23621.72 USD — | — - | 3.54B USD — |
| US Tech Global Market Composite NQGM | 2346.16 USD — |
+0.86
|
— — | 2326.43 USD — | 2347.01 USD — | — - | — — |
| US Tech Biotechnology NBI | 5843.74 USD — |
+0.69
|
— — | 5812.05 USD — | 5851.25 USD — | — - | — — |
| US Tech Health Care IXHC | 1212.11 USD — |
+0.55
|
— — | 1206.25 USD — | 1213.6 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2677.67 USD — |
+0.4
|
— — | 2663.83 USD — | 2679.59 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}